Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Combined with EGFR-TKI for Leptomeningeal Metastases from Lung Cancer
NCT04833205Phase 2Unknown
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in leptomeningeal metastases (LM) and non-small cell lung cancer (NSCLC). Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
leptomeningeal metastases (LM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04833205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04833205.